Adding exercise training to rosuvastatin treatment: influence on serum lipids and biomarkers of muscle and liver damage

Metabolism: Clinical and Experimental

Volumn 58, Issue 7, 2009, Pages 1030-1038

  Coen, Paul M ^a   Flynn, Michael G ^a   Markofski, Melissa M ^a   Pence, Brandt D ^a   Hannemann, Robert E ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BIOLOGICAL MARKER; CHOLESTEROL; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; ENDURANCE; EXERCISE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIVER INJURY; MALE; MUSCLE FATIGUE; MUSCLE INJURY; MUSCLE STIFFNESS; MYALGIA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TRAINING; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ALANINE TRANSAMINASE; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CREATINE KINASE; EXERCISE; FEMALE; FLUOROBENZENES; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES;

EID: 66349125864     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.03.006     Document Type: Article

References (53)

1. Miller N.E., Thelle D.S., Forde O.H., and Mjos O.D. The Tromso heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1 (1977) 965-968
2. Sharrett A.R., Patsch W., Sorlie P.D., Heiss G., Bond M.G., and Davis C.E. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 14 (1994) 1098-1104
3. Pedersen T.R., Olsson A.G., and Faergeman O. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
4. LIPID. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339 (1998) 1349-1357
5. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323 (1990) 1289-1298
6. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360 (2002) 1623-1630
7. Maron D.J., Fazio S., and Linton M.F. Current perspectives on statins. Circulation 101 (2000) 207-213
8. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 335 (1996) 1001-1009
9. Shepherd J. Statin therapy in clinical practice: new developments. Curr Opin Lipidol 6 (1995) 254-255
10. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (1998) 1615-1622
11. Blasetto J.W., Stein E.A., Brown W.V., Chitra R., and Raza A. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 91 (2003) 3C-10C [discussion C]
12. Jones P.H., Davidson M.H., Stein E.A., Bays H.E., McKenney J.M., Miller E., et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 92 (2003) 152-160
13. Fletcher G.F., Balady G., Blair S.N., Blumenthal J., Caspersen C., Chaitman B., et al. Statement on exercise: benefits and recommendations for physical activity programs for all Americans. A statement for health professionals by the Committee on Exercise and Cardiac Rehabilitation of the Council on Clinical Cardiology, American Heart Association. Circulation 94 (1996) 857-862
14. Berlin J.A., and Colditz G.A. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol 132 (1990) 612-628
15. Kohl III H.W. Physical activity and cardiovascular disease: evidence for a dose response. Med Sci Sports Exerc 33 6 Suppl (2001) S472-S483 [discussion S93-4]
16. Durstine J.L., and Haskell W. Effects of exercise training on plasma lipids and lipoproteins. In: Holloszy J. (Ed). Exercise and sports science reviews (1994), Williams and Wilkins, Philadelphia (Pa) 477-521
17. Durstine J.L., Crouse S.F., and Moffatt R. Lipids in exercise and sports. In: Driskell J., and Wolinsky I. (Eds). Energy-yielding macronutrients and energy metabolism in sports nutrition (2000), CRC Press, Boca Raton (Fla) 87-117
18. Halbert J.A., Silagy C.A., Finucane P., Withers R.T., and Hamdorf P.A. Exercise training and blood lipids in hyperlipidemic and normolipidemic adults: a meta-analysis of randomized, controlled trials. Eur J Clin Nutr 53 (1999) 514-522
19. Leon A.S., and Sanchez O.A. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc 33 6 Suppl (2001) S502-S515 [discussion S28-9]
20. Tran Z.V., Weltman A., Glass G.V., and Mood D.P. The effects of exercise on blood lipids and lipoproteins: a meta-analysis of studies. Med Sci Sports Exerc 15 (1983) 393-402
21. Herzberg G.R. Aerobic exercise, lipoproteins, and cardiovascular disease: benefits and possible risks. Can J Appl Physiol 29 (2004) 800-807
22. Elosua R., Molina L., Fito M., Arquer A., Sanchez-Quesada J.L., Covas M.I., et al. Response of oxidative stress biomarkers to a 16-week aerobic physical activity program, and to acute physical activity, in healthy young men and women. Atherosclerosis 167 (2003) 327-334
23. Sinzinger H., Schmid P., and O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis 143 (1999) 459-460
24. Sinzinger H., Lupattelli G., Chehne F., Oguogho A., and Furberg C.D. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J Clin Pharm Ther 26 (2001) 303-310
25. Manoukian A.A., Bhagavan N.V., Hayashi T., Nestor T.A., Rios C., and Scottolini A.G. Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 36 (1990) 2145-2147
26. Law M., and Rudnicka A.R. Statin safety: a systematic review. Am J Cardiol 97 (2006) 52C-60C
27. Grundy S.M. Statin therapy in older persons: pertinent issues. Arch Intern Med 162 (2002) 1329-1331
28. Kuipers H. Exercise-induced muscle damage. Int J Sports Med 15 (1994) 132-135
29. Thompson P.D., Gadaleta P.A., Yurgalevitch S., Cullinane E., and Herbert P.N. Effects of exercise and lovastatin on serum creatine kinase activity. Metabolism 40 (1991) 1333-1336
30. Thompson P.D., Zmuda J.M., Domalik L.J., Zimet R.J., Staggers J., and Guyton J.R. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 46 (1997) 1206-1210
31. Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
32. Sinzinger H., and O'Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 57 (2004) 525-528
33. NCEP. Executive summary of third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
34. ACSM, Kenney W.L., Humphrey R.H., Bryant C.X., and Mahler D.A. ACSM's guidelines for exercise testing and prescription. 5th ed. (1995), Williams & Wilkins, Baltimore (Md)
35. Paffenbarger Jr. R.S., Blair S.N., Lee I.M., and Hyde R.T. Measurement of physical activity to assess health effects in free-living populations. Med Sci Sports Exerc 25 (1993) 60-70
36. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
37. Davidson M., Ma P., Stein E.A., Gotto Jr. A.M., Raza A., Chitra R., et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 89 (2002) 268-275
38. Schneck D.W., Knopp R.H., Ballantyne C.M., McPherson R., Chitra R.R., and Simonson S.G. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 91 (2003) 33-41
39. Olsson A.G., Pears J., McKellar J., Mizan J., and Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am J Cardiol 88 (2001) 504-508
40. Wittke R. Effect of fluvastatin in combination with moderate endurance training on parameters of lipid metabolism. Sports Med 27 (1999) 329-335
41. Ndrepepa G., Braun S., von Beckerath N., Mehilli J., Gorchakova O., Vogt W., et al. Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease. Clin Chim Acta 360 (2005) 178-186
42. Ehara S., Ueda M., Naruko T., Haze K., Itoh A., Otsuka M., et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103 (2001) 1955-1960
43. Miller Y.I., Chang M.K., Binder C.J., Shaw P.X., and Witztum J.L. Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 14 (2003) 437-445
44. Ehara S., Ueda M., Naruko T., Haze K., Matsuo T., Ogami M., et al. Pathophysiological role of oxidized low-density lipoprotein in plaque instability in coronary artery diseases. J Diabet Complications 16 (2002) 60-64
45. Itabe H., and Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J Atheroscler Thromb 14 (2007) 1-11
46. Resch U., Tatzber F., Budinsky A., and Sinzinger H. Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy. Br J Clin Pharmacol 61 (2006) 262-274
47. Thallinger C., Urbauer E., Lackner E., Graselli U., Kostner K., Wolzt M., et al. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int J Clin Pharmacol Ther 43 (2005) 551-557
48. van Tits L.J., van Himbergen T.M., Lemmers H.L., de Graaf J., and Stalenhoef A.F. Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 185 (2006) 307-312
49. Verreth W., De Keyzer D., Davey P.C., Geeraert B., Mertens A., Herregods M.C., et al. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice. Br J Pharmacol 151 (2007) 347-355
50. Miyagishima K., Hiramitsu S., Kato S., Kato Y., Kitagawa F., Teradaira R., et al. Efficacy of atorvastatin therapy in ischaemic heart disease-effects on oxidized low-density lipoprotein and adiponectin. J Int Med Res 35 (2007) 534-539
51. Inami S., Okamatsu K., Takano M., Takagi G., Sakai S., Sano J., et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J 45 (2004) 969-975
52. van der Zwan L.P., Teerlink T., Dekker J.M., Henry R.M., Stehouwer C.D., Jakobs C., et al. Circulating oxidized LDL: determinants and association with brachial flow-mediated dilation. J Lipid Res 50 (2009) 342-349
53. Tolman K.G. The liver and lovastatin. Am J Cardiol 89 (2002) 1374-1380